A detailed history of Disciplina Capital Management LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Disciplina Capital Management LLC holds 688 shares of LLY stock, worth $621,064. This represents 0.02% of its overall portfolio holdings.

Number of Shares
688
Previous 272 152.94%
Holding current value
$621,064
Previous $212 Million 34.38%
% of portfolio
0.02%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$724.87 - $909.04 $301,545 - $378,160
416 Added 152.94%
688 $139 Million
Q4 2023

Feb 05, 2024

BUY
$525.19 - $619.13 $525 - $619
1 Added 0.37%
272 $159 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $117,803 - $162,410
271 New
271 $146 Million
Q2 2023

Nov 16, 2023

BUY
$350.74 - $468.98 $37,529 - $50,180
107 Added 65.24%
271 $127 Million
Q1 2023

Nov 16, 2023

SELL
$310.63 - $364.82 $5,280 - $6,201
-17 Reduced 10.37%
147 $50.3 Million
Q4 2022

Nov 16, 2023

SELL
$321.55 - $374.67 $10,289 - $11,989
-32 Reduced 16.33%
164 $60 Million
Q3 2022

Nov 16, 2023

SELL
$296.48 - $337.87 $31,723 - $36,152
-107 Reduced 39.48%
164 $52.9 Million
Q2 2022

Nov 16, 2023

BUY
$278.73 - $327.27 $278 - $327
1 Added 0.51%
196 $63.6 Million
Q1 2022

Nov 16, 2023

BUY
$234.69 - $291.66 $938 - $1,166
4 Added 2.09%
195 $55.9 Million
Q4 2021

Nov 16, 2023

SELL
$224.85 - $279.04 $11,917 - $14,789
-53 Reduced 19.56%
218 $60.1 Million
Q3 2021

Nov 16, 2023

BUY
$221.6 - $272.71 $1,772 - $2,181
8 Added 4.37%
191 $44.1 Million
Q2 2021

Nov 16, 2023

BUY
$180.55 - $233.54 $4,874 - $6,305
27 Added 17.31%
183 $42.1 Million
Q1 2021

Nov 16, 2023

BUY
$164.32 - $212.72 $9,037 - $11,699
55 Added 54.46%
156 $29.1 Million
Q4 2020

Nov 16, 2023

SELL
$130.46 - $172.63 $22,178 - $29,347
-170 Reduced 62.73%
101 $17.1 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $858B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Disciplina Capital Management LLC Portfolio

Follow Disciplina Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Disciplina Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Disciplina Capital Management LLC with notifications on news.